Prospects of current AXL-targeting therapies in early phase cancer trials [0.03%]
AXL靶向疗法在早期癌症试验中的前景
Juhye Yim,Chloe Hope,Justus M Huelse et al.
Juhye Yim et al.
Introduction: AXL, a member of the TAM (TYRO3, AXL, and MERTK) family of receptor tyrosine kinases, controls pro-tumorigenic signaling cascades and cancer-immunological functions, and promotes drug resistance. Due to AXL'...
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD [0.03%]
HY-072808乳膏（一种新型磷酸二酯酶4抑制剂）在轻中度特应性皮炎青少年和成人患者中的安全性、药代动力学及疗效研究
Feng Yao,Mingchao He,Jing Wang et al.
Feng Yao et al.
Background: HY-072808 is a new PDE4 inhibitor with potential anti- atopic dermatitis (AD) effects. This study aimed to investigate its safety and pharmacokinetics in healthy individuals, and subsequently, its safety, phar...
Prospects for multi-focal motor neuropathy treatment by complement inhibition [0.03%]
补体抑制治疗多焦motor神经病的前景
Hans Katzberg,Carlos Alberto Soto Rincón
Hans Katzberg
Zhipeng Cao,Laura D Osellame,Laura Allan et al.
Zhipeng Cao et al.
Role of ROCK2 inhibitors in the Treatment of Chronic Graft-versus-Host disease [0.03%]
ROCK2抑制剂在慢性移植物抗宿主病治疗中的作用
Dat Ngo,Jose Tinajero,Salman Otoukesh et al.
Dat Ngo et al.
Introduction: Chronic graft-versus-host disease (cGVHD) is the most common cause of late non-relapse mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Rho-associated coiled-coiled kinases (ROCK) in...
Preclinical development of siRNA conjugates to target tumor antigens [0.03%]
针对肿瘤抗原的siRNA缀合物的临床前开发研究
Takanori Kubo,Toshio Seyama
Takanori Kubo
A randomized, phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men [0.03%]
一项在健康日本男性中评估TRPC6抑制剂BI 764198的安全性、耐受性和药代动力学的I期随机试验
Takuma Yonemura,Akiko Sarashina,Yoshifumi Tachibana et al.
Takuma Yonemura et al.
Background: BI 764,198 is a selective, oral transient receptor potential cation channel, subfamily C, member 6 inhibitor under investigation for focal segmental glomerulosclerosis. ...
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer [0.03%]
注射性环肽偶联毒素zelentuxitecan（bt-8009）：靶向膀胱癌nectin-4的治疗药物
Antonio Cigliola,Valentina Tateo,Ravasi Michela et al.
Antonio Cigliola et al.
Introduction: Zelenectide pevedotin (BT8009) is a novel Bicycle Toxin Conjugate targeting nectin-4, designed to overcome the limitations of already existing anti-nectin-4 antibody-drug conjugates such as enfortumab vedoti...
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL) in healthy male adults [0.03%]
一项在健康成人男性受试者中评估AVT03（70毫克/毫升）候选药用生物类似物与原研参照药的单次给药后的药代动力学相似性、安全性和耐受性的随机双盲平行对照临床试验
Monika Tomaszewska-Kiecana,Felicitas Bullo,Lukasz Jaskiewicz et al.
Monika Tomaszewska-Kiecana et al.
Background: This study (NCT05876949) compared the pharmacokinetic (PK) similarity, safety, and immunogenicity of AVT03, a candidate biosimilar, with reference product (RP) denosumab (Xgeva). ...
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (60 mg/mL) in healthy male adults [0.03%]
评估AVT03(60毫克/毫升)与原研修美安药代动力学相似性，以及在健康成年男性受试者中的药效学、安全性、耐受性和免疫原性的随机双盲平行对照组试验
Anel Pretorius,Felicitas Bullo,Lukasz Jaskiewicz et al.
Anel Pretorius et al.
Background: This study compared pharmacokinetic (PK) similarity, pharmacodynamic, safety, and immunogenicity of AVT03, a candidate biosimilar, with reference product (RP) denosumab (Prolia). ...